Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of a Silicon Carbide Coated Stent versus a Noncoated Stent in Humans:

Comparison of a Silicon Carbide Coated Stent versus a Noncoated Stent in Humans: Purpose: Stents coated with hypothrombogenic silicon carbide (a‐SiC:H) exhibited low restenosis rates in the rabbit and in an observational study in humans. Thus, the clinical and angiographic outcome was assessed in a large multicenter study. Material and Methods: Four hundred and ninety‐seven patients (63.4 ± 9.8 years) were randomized to either receive the a‐SiC:H‐coated Tenax™ stent or the stainless steel Nir™ stent. Lesions (diameter ≥2.8 mm, length <20 mm) were covered with one single stent. Results: Fifty‐one of 497 (10.3%) patients were excluded for protocol violation. Three hundred and forty‐two of 446 (76.7%) patients presented for scheduled angiographic follow‐up after 4.7 ± 1.2 months and 29 of 446 (6.5%) prematurely. In‐hospital complications comprised two deaths (0.8%) (P > 0.99) and one (0.4%) (P > 0.99) CK‐elevation in each group, target lesion revascularization in 5 of 250 (2%) of the Tenax™ and 4 of 244 (1.6%) of the Nir™ sample (P > 0.99), and subacute thrombosis in 2 of 250 (0.8%) of the Tenax™ patients (P = 0.5). In the Tenax™/Nir™ patients mean percent diameter stenosis decreased from 82.3 ± 9.1%/80.7 ± 8.4% (P = 0.49) to 17.6 ± 5.5%/17.6 ± 5.5% (P = 0.99) postprocedure and increased to 34.5 ± 21.5%/34.2 ± 23.1% (P = 0.90) at follow‐up. Conclusions: Thus, there appears to be no advantage of the silicon carbide coated stent over a stainless steel stent after 4.7 ± 1.2 months with regard to clinical and angiographic restenosis rates. (J Interven Cardiol 2003;16:325–333) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Loading next page...
 
/lp/wiley/comparison-of-a-silicon-carbide-coated-stent-versus-a-noncoated-stent-qqd7o0uOzi

References (53)

Publisher
Wiley
Copyright
Copyright © 2003 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1034/j.1600-6143.2003.08058.x
Publisher site
See Article on Publisher Site

Abstract

Purpose: Stents coated with hypothrombogenic silicon carbide (a‐SiC:H) exhibited low restenosis rates in the rabbit and in an observational study in humans. Thus, the clinical and angiographic outcome was assessed in a large multicenter study. Material and Methods: Four hundred and ninety‐seven patients (63.4 ± 9.8 years) were randomized to either receive the a‐SiC:H‐coated Tenax™ stent or the stainless steel Nir™ stent. Lesions (diameter ≥2.8 mm, length <20 mm) were covered with one single stent. Results: Fifty‐one of 497 (10.3%) patients were excluded for protocol violation. Three hundred and forty‐two of 446 (76.7%) patients presented for scheduled angiographic follow‐up after 4.7 ± 1.2 months and 29 of 446 (6.5%) prematurely. In‐hospital complications comprised two deaths (0.8%) (P > 0.99) and one (0.4%) (P > 0.99) CK‐elevation in each group, target lesion revascularization in 5 of 250 (2%) of the Tenax™ and 4 of 244 (1.6%) of the Nir™ sample (P > 0.99), and subacute thrombosis in 2 of 250 (0.8%) of the Tenax™ patients (P = 0.5). In the Tenax™/Nir™ patients mean percent diameter stenosis decreased from 82.3 ± 9.1%/80.7 ± 8.4% (P = 0.49) to 17.6 ± 5.5%/17.6 ± 5.5% (P = 0.99) postprocedure and increased to 34.5 ± 21.5%/34.2 ± 23.1% (P = 0.90) at follow‐up. Conclusions: Thus, there appears to be no advantage of the silicon carbide coated stent over a stainless steel stent after 4.7 ± 1.2 months with regard to clinical and angiographic restenosis rates. (J Interven Cardiol 2003;16:325–333)

Journal

Journal of Interventional CardiologyWiley

Published: Aug 1, 2003

There are no references for this article.